AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced that Jade Pharmaceutical Inc., the registration agent in China for AMDL, has submitted an application with the China State Food and Drug Administration (SDFA) for approval to market AMDL's DR-70® cancer test. The SDFA has begun the approval process and DR-70® is undergoing standard product review by the Beijing Institute of Medical Device Quality Supervision and Inspection Center.

The worldwide market for cancer diagnostics (including in vitro diagnostics such as AMDL's DR-70®) is expected to increase from approximately $4.1 billion in 2004 to an estimated $7.4 billion in 2009. With more than 3 million cancer patients in China, the disease is one of the major causes of death in urban areas and especially in people 65 and older. Chinese government officials see early detection as a key to cutting the morbidity and mortality rate for cancer as well as stemming the costs for treating this disease in its advanced stages.

With a growing urban and rapidly aging population, and the increasing trend toward health awareness by the Chinese people, there is a significant market for cancer diagnostics in China. As living standards increase, promoted by enormous economic development in China, the market demand for early stage cancer detection is certain to grow. It is estimated this year-over-year growth will be 10 percent going forward.

Source:佚名